Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2015.10.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[UPFRONT DOCETAXEL WITH ANDROGEN DEPRIVATION THERAPY IN MALES WITH HIGH-VOLUME METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: RESULTS OF A SINGLE-INSTITUTION SERIES].
Nihon Hinyokika Gakkai Zasshi
January 2025
Department of Urology, Jikei University of Medicine.
(Objective) This study aimed at evaluating the efficacy and safety of upfront docetaxel (DTX) treatment and androgen deprivation therapy (ADT) in male patients with high-volume metastatic castration-sensitive prostate cancer (HV-mCSPC). (Methods) This retrospective study was conducted using the medical records of 30 patients treated for HV-mCSPC by using upfront DTX treatment along with ADT at Atsugi City Hospital between December 2015 and December 2022. The patient characteristics, demographics, oncological outcomes, adverse events, and sequential therapy were evaluated.
View Article and Find Full Text PDFTriplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence.
Int J Urol
December 2024
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Prostate cancer (PC) growth is hormone-dependent and it frequently develops distant metastases as disease progresses. Patients with metastatic castration-sensitive prostate cancer (mCSPC) initially respond to androgen deprivation therapy (ADT) but eventually become refractory and develop metastatic castration-resistant prostate cancer (mCRPC). Castration-resistance is associated with high lethality and metastases confer poor prognosis, therefore unmet needs in treatment for mCSPC remain high.
View Article and Find Full Text PDFEfficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
November 2024
Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.
Background: The 2 × 2 PEACE-1 study showed that combining androgen-deprivation therapy with docetaxel and abiraterone improved overall and radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer. We aimed to examine the efficacy and safety of adding radiotherapy in this population.
Methods: We conducted an open-label, randomised, controlled, phase 3 trial with a 2 × 2 factorial design (PEACE-1) at 77 hospitals across Europe.
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.
Can Urol Assoc J
August 2024
The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Introduction: Treatment intensification beyond androgen deprivation therapy (ADT) has shown survival benefit in patients with metastatic castration-sensitive prostate cancer (mCSPC). There is a need to better understand how these novel treatments fit in real-world practice.
Methods: Using electronic medical records and administrative data, a population-based, retrospective cohort study of patients newly diagnosed with de novo mCSPC between 2010 and 2020 in Alberta, Canada, and initiated ADT was conducted.
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.
Future Oncol
January 2025
ANZUP Cancer Trials Group, Sydney, NSW, Australia.
What Is This Summary About?: This summary includes information from the ARCHES and ENZAMET . Both studies looked at enzalutamide treatment for people with metastatic hormone-sensitive prostate cancer (known as mHSPC). In ARCHES, researchers compared the medications enzalutamide + androgen deprivation therapy (known as ADT) with + ADT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!